Transdermal contraceptive patch - a new birth control option
Banerjee S
Record ID 32002000297
English, French
Authors' objectives:
To summarise the available evidence on the transdermal contraceptive patch.
Authors' recommendations:
- A new, once-weekly contraceptive patch (Ortho Evra TM) that delivers transdermally norelgestromin and ethinyl estradiol was approved by the U.S. FDA November, 2001.
- Patch drug delivery systems theoretically offer advantages over oral therapy, including enhanced adherence to treatment regimen and reduction in adverse events.
- A randomized controlled trial (RCT) demonstrated better adherence to the treatment regimen, with the patch when compared to an oral contraceptive (OC).
- However withdrawals due to adverse events and participant choice were higher in patch users than in OC users.
- An RCT covering six or 13 menstrual cycles indicated that the short-term efficacy of the patch was similar to that of the OC, but the risk of pregnancy in the long term is not known.
Authors' methods:
Overview
Details
Project Status:
Completed
URL for project:
https://www.ccohta.ca/research/index.html
Year Published:
2001
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Canada
MeSH Terms
- Contraception
- Contraceptive Agents, Female
Contact
Organisation Name:
Canadian Coordinating Office for Health Technology Assessment
Contact Address:
600-865 Carling Avenue, Ottawa, ON K1S 5S8 Canada. Tel: +1 613 226 2553, Fax: +1 613 226 5392;
Contact Name:
requests@cadth.ca
Contact Email:
requests@cadth.ca
Copyright:
Canadian Coordinating Office for Health Technology Assessment
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.